Business Model Breakdown
How PAVmed Inc Makes Money
PAVM
Market Cap
$59M
Annual Revenue
$29,000
Profit Margin
564.8%
Employees
39
The Short Version
PAVmed Inc. is a medical technology company focused on commercializing innovative devices and diagnostics for unmet clinical needs. Its primary operations are through its majority-owned subsidiary, Lucid Diagnostics, which markets EsoGuard and EsoCheck, non-invasive tests for early detection of esophageal precancer. PAVmed also operates Veris Health, developing an implantable cardiac monitor aimed at cancer patients. The company generates revenue through the sales of these diagnostic tests and anticipated sales of medical devices, targeting healthcare providers, clinics, and government health systems to improve patient outcomes.
Where the Revenue Comes From
Lucid Diagnostics (EsoGuard test sales - ~97% of reported consolidated Q4 2025 revenue; deconsolidated from Q1 2025)
PAVmed Inc. direct revenue (minimal, $52,000 in Q4 2025)
Veris Health device sales (future revenue stream upon regulatory approval and launch)
Who buys: Healthcare providers, gastroenterologists, primary care physicians, Veterans Affairs (VA) health system, and potentially oncology centers.
Why It Works (Competitive Advantages)
- ✔FDA 510(k) clearance for EsoGuard and EsoCheck, enabling non-endoscopic esophageal precancer screening.
- ✔Proprietary technology for less invasive diagnostic procedures.
- ✔Growing real-world data demonstrating EsoGuard's clinical utility (over 12,000 patients).
Economic Moat: Narrow (Intangible Assets/IP (FDA clearances, patents for EsoGuard and Veris technology), Switching Costs (potential for physicians to integrate EsoGuard into standard screening protocols once adopted))
What Our Analysis Says
DVR Score as of April 24, 2026
PAVmed Inc. (PAVM) remains a highly speculative, high-risk, high-reward investment, yet its financial runway has materially improved since the last analysis. The completion of a $30M Series D preferred stock and $15M senior secured note financing provides a crucial $45M capital infusion, significantly alleviating the immediate cash burn and precarious financial position that previously justified a lower score. Commercialization of Lucid Diagnostics' EsoGuard shows nascent QoQ volume growth (29%), and Veris Health's implantable monitor is progressing toward late 2026 FDA 510(k). However, PAVmed's direct revenue remains negligible ($52k in Q4 2025), and operating expenses are high ($6.9M/quarter), meaning profitability is distant. Significant future dilution is highly likely given the S-3 filing for 9.23M shares, offsetting much of the financial improvement for common shareholders. The path to 10x growth hinges entirely on an accelerated, sustained commercialization ramp for EsoGuard and successful Veris Health launch, which remains highly uncertain. **Score Change Explanation:** The new score of 33/100 (up from 3/100) is primarily justified by the material improvement in the company's financial health and runway. The $45M capital raise completed on March 30, 2026, directly addresses the 'persistent cash burn' and 'precarious financial position' cited in the previous analysis. This funding provides approximately 6-7 quarters of operating capital based on current expense levels. Additionally, Lucid Diagnostics (deconsolidated subsidiary) showed 29% QoQ volume growth for EsoGuard, indicating some progress in commercialization efforts. While still deeply unprofitable and facing significant dilution risks, the immediate survival risk has been substantially mitigated, warranting a significant upward adjustment from the previous, near-zero assessment.